Trial Profile
A Dose Tolerability and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Sep 2019
Price :
$35
*
At a glance
- Drugs RX 0201 (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 28 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Aug 2012 Endpoints (Objective clinical response, biomarker levels, vascular endothelial growth factor levels) added from Rexahn Pharmaceuticals website.
- 28 Sep 2011 Preliminary results are expected in the first half of 2012, according to a Rexahn Pharmaceuticals media release.